다형성교모세포종 치료 시장 보고서 : 약물 유형, 투여 경로, 분자 유형, 유통 채널, 지역별(2024-2032년)

The global glioblastoma multiforme treatment market size reached US$ 2.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 3.9 Billion by 2032, exhibiting a growth rate (CAGR) of 6.7% during 2024-2032.

Glioblastoma multiforme, also known as grade IV astrocytoma, is a malignant grade IV brain tumor that rapidly spreads within the brain cells and can also infect the nearby cells. Since it is characterized by rapid cell degeneration, it creates immense pressure on the brain resulting in severe headaches and seizures. Although the exact cause of the diseases is still unknown, several factors including rare hereditary disorders such as Turcot syndrome are believed to be its cause. It is one of the most lethal forms of brain cancer and is treatment-resistant in nature, wherein the patient has an extremely short survival period post-diagnosis. The current treatment procedure of the disease includes surgical resection, chemotherapy and radiation.

Increasing prevalence of oncological diseases and a growing geriatric population across the globe are among the key factors driving the market growth. Furthermore, the development of advanced treatment methods that counter the resistive properties of glioma stem cells is also positively influencing the market growth. Additionally, increasing research and development (R&D) activities in molecular biotechnology and gene therapy for cancer and related diseases have facilitated the development of various biological drugs. These drugs assist in diminishing the side-effects of the existing treatment methods, thus creating broader acceptance amongst patients. Moreover, initiatives undertaken by several governments across the globe to improve healthcare infrastructure, along with the rising awareness of the availability of various therapies, are further expected to create a positive outlook for the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global glioblastoma multiforme treatment market report, along with forecasts at the global and regional level from 2024-2032. Our report has categorized the market based on drug type, route of administration, type of molecule, and distribution channel.

Breakup by Drug Type:

Temozolomide

Bevacizumab

Carmustine

Radiosensitizers

Others

Breakup by Route of Administration:

Oral

Parenteral

Breakup by Type of Molecule:

Small Molecule

Biologics

Breakup by Distribution Channel:

Hospitals

Pharmacies

Others

Breakup by Region:

North America

Europe

Asia Pacific

Middle East and Africa

Latin America

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Sun Pharmaceutical Industries, Celldex Therapeutics, Pfizer, F. Hoffmann La Roche, Bristol-Myers Squibb, Teva Pharmaceuticals, Exelixis, Angiochem and Arbor Pharmaceuticals.

IMARC Group's latest report provides a deep insight into the global glioblastoma multiforme treatment market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the glioblastoma multiforme treatment market in any manner.

Key Questions Answered in This Report

• 1. What was the size of the global glioblastoma multiforme treatment market in 2023?
• 2. What is the expected growth rate of the global glioblastoma multiforme treatment market during 2024-2032?
• 3. What are the key factors driving the global glioblastoma multiforme treatment market?
• 4. What has been the impact of COVID-19 on the global glioblastoma multiforme treatment market?
• 5. What is the breakup of the global glioblastoma multiforme treatment market based on the route of administration?
• 6. What is the breakup of the global glioblastoma multiforme treatment market based on the type of molecule?
• 7. What is the breakup of the global glioblastoma multiforme treatment market based on the distribution channel?
• 8. What are the key regions in the global glioblastoma multiforme treatment market?
• 9. Who are the key players/companies in the global glioblastoma multiforme treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Glioblastoma Multiforme Treatment Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Breakup by Drug Type
• 5.5 Market Breakup by Route of Administration
• 5.6 Market Breakup by Type of Molecule
• 5.7 Market Breakup by Distribution Channel
• 5.8 Market Breakup by Region
• 5.9 Market Forecast

6 Market Breakup by Drug Type

• 6.1 Temozolomide
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Bevacizumab
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Carmustine
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Radiosensitizers
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Others
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast

7 Market Breakup by Route of Administration

• 7.1 Oral
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Parenteral
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Type of Molecule

• 8.1 Small Molecule
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Biologics
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast

9 Market Breakup by Distribution Channel

• 9.1 Hospitals
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Pharmacies
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Others
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 Market Trends
  • 10.1.2 Market Forecast
• 10.2 Europe
  • 10.2.1 Market Trends
  • 10.2.2 Market Forecast
• 10.3 Asia Pacific
  • 10.3.1 Market Trends
  • 10.3.2 Market Forecast
• 10.4 Middle East and Africa
  • 10.4.1 Market Trends
  • 10.4.2 Market Forecast
• 10.5 Latin America
  • 10.5.1 Market Trends
  • 10.5.2 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Sun Pharmaceutical Industries
  • 15.3.2 Celldex Therapeutics
  • 15.3.3 Pfizer
  • 15.3.4 F. Hoffmann La Roche
  • 15.3.5 Bristol-Myers Squibb
  • 15.3.6 Teva Pharmaceuticals
  • 15.3.7 Exelixis
  • 15.3.8 Angiochem
  • 15.3.9 Arbor Pharmaceuticals